Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares US Real Estate ETF
IYR
|
+$947M |
| 2 |
Tesla
TSLA
|
+$608M |
| 3 |
Microsoft
MSFT
|
+$444M |
| 4 |
Accenture
ACN
|
+$409M |
| 5 |
iShares MSCI Emerging Markets ETF
EEM
|
+$396M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.06B |
| 2 |
Texas Instruments
TXN
|
+$1.92B |
| 3 |
Meta Platforms (Facebook)
META
|
+$1.81B |
| 4 |
Starbucks
SBUX
|
+$1.42B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$1,000M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.52% |
| 2 | Financials | 7.13% |
| 3 | Consumer Discretionary | 6.46% |
| 4 | Healthcare | 5.43% |
| 5 | Communication Services | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3401
Alector
ALEC
$168M
| $824K | ﹤0.01% |
176,800
+100,731
| +132% | +$540K |
|
|
TRML
3402
DELISTED
Tourmaline Bio
TRML
| $818K | ﹤0.01% |
31,833
+23,536
| +284% | +$393K |
|
|
ENFN
3403
DELISTED
Enfusion, Inc.
ENFN
| $817K | ﹤0.01% |
86,039
+61,554
| +251% | +$531K |
|
3404
Applied Optoelectronics
AAOI
$7.57B
| $815K | ﹤0.01% |
56,920
+15,507
| +37% | +$161K |
|
|
BKV
3405
BKV Corp
BKV
$2.68B
| $814K | ﹤0.01% |
+44,500
| New | +$806K |
|
|
VRN
3406
DELISTED
Veren
VRN
| $813K | ﹤0.01% |
132,245
+100,279
| +314% | +$717K |
|
3407
Acco Brands
ACCO
$389M
| $811K | ﹤0.01% |
148,302
+109,813
| +285% | +$555K |
|
3408
iShares MSCI USA Momentum Factor ETF
MTUM
$25B
| $810K | ﹤0.01% |
3,997
-61
| -2% | -$11.8K |
|
3409
Opko Health
OPK
$985M
| $810K | ﹤0.01% |
543,336
+329,870
| +155% | +$490K |
|
3410
Anika Therapeutics
ANIK
$258M
| $807K | ﹤0.01% |
32,664
+13,054
| +67% | +$338K |
|
3411
GeneDx Holdings
WGS
$1.93B
| $803K | ﹤0.01% |
18,921
+14,681
| +346% | +$496K |
|
3412
Celcuity
CELC
$4.21B
| $799K | ﹤0.01% |
53,605
+45,576
| +568% | +$751K |
|
3413
CALL
Wolfspeed
WOLF
$1.23B
| $798K | ﹤0.01% |
+82,300
| New | +$1.21M |
|
3414
First Bank
FRBA
$464M
| $797K | ﹤0.01% |
52,462
+20,602
| +65% | +$300K |
|
|
GOOS
3415
CALL
Canada Goose Holdings
GOOS
$872M
| $797K | ﹤0.01% |
+63,600
| New | +$721K |
|
3416
Hudbay
HBM
$10.1B
| $795K | ﹤0.01% |
86,475
+83,036
| +2,415% | +$669K |
|
3417
Forrester Research
FORR
$223M
| $794K | ﹤0.01% |
44,090
+18,319
| +71% | +$334K |
|
3418
PUT
Atlassian
TEAM
$25.6B
| $794K | ﹤0.01% |
+5,000
| New | +$822K |
|
3419
Corbus Pharmaceuticals
CRBP
$166M
| $793K | ﹤0.01% |
38,462
-53,266
| -58% | -$2.73M |
|
|
TERN
3420
DELISTED
Terns Pharmaceuticals
TERN
| $791K | ﹤0.01% |
94,902
-100,540
| -51% | -$827K |
|
3421
Mayville Engineering Co
MEC
$654M
| $790K | ﹤0.01% |
37,486
+11,489
| +44% | +$215K |
|
3422
Gogo Inc
GOGO
$565M
| $790K | ﹤0.01% |
109,959
+85,925
| +358% | +$701K |
|
3423
PUT
Joby Aviation
JOBY
$7.03B
| $789K | ﹤0.01% |
+156,800
| New | +$853K |
|
3424
Real Brokerage
REAX
$349M
| $784K | ﹤0.01% |
141,188
+108,928
| +338% | +$619K |
|
3425
Pulmonx
LUNG
$68.8M
| $780K | ﹤0.01% |
94,109
+1,679
| +2% | +$12.1K |
|
Similar funds
Barclays's Q3 2024 Portfolio in Review
As of Q3 2024, Barclays held 5,593 positions worth $377B, up 15% from $327B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Barclays deployed $31.3B of net new capital in Q3 2024, opening 785 new positions and adding to 2,954 existing holdings. Its largest new stake was Smurfit Westrock: 3,460,710 shares worth $171M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was CRH, an estimated $2.06B trimmed.
- Barclays's largest Q3 2024 buy was Smurfit Westrock: 3,460,710 shares worth $171M.
- Barclays added most to iShares US Real Estate ETF in Q3 2024, an estimated $947M increase.
- Barclays's biggest Q3 2024 reduction was CRH, cutting an estimated $2.06B.
- Barclays fully exited Equitrans Midstream Corporation Common Stock in Q3 2024, selling an estimated $51.3M.
- Barclays's ten largest holdings make up 41% of its $377B portfolio in Q3 2024.
- Barclays opened 785 new positions and closed 322 in Q3 2024.
- Barclays's portfolio value rose 15% quarter-over-quarter to $377B.
Based on Barclays's 13F filing for Q3 2024, filed 15 Nov 2024.